Pharmacovigilance and Drug Safety Software - Market Insights, Competitive Landscape, and Market Forecast - 2034

Pharmacovigilance and Drug Safety Software Market Summary

Overview:

• The global pharmacovigilance and drug safety software market was valued at USD 1.62 billion in 2025 and is projected to reach USD 3.94 billion by 2034.
• The market is expected to expand at a CAGR of 10.4% during the forecast period 2026-2034, supported by the rising volume of adverse event reports, the tightening of global pharmacovigilance regulations, the adoption of artificial intelligence and automation in case processing, and the shift toward cloud and software-as-a-service deployment.
• By software type, the adverse event reporting and case management segment dominated the pharmacovigilance and drug safety software market with a 38% share in 2025.
• By delivery mode, the cloud-based segment dominated the pharmacovigilance and drug safety software market with a 58% share in 2025.
• By end-user, the pharmaceutical and biotechnology companies segment dominated the pharmacovigilance and drug safety software market with a 62% share in 2025.
• North America accounted for the largest share of the pharmacovigilance and drug safety software market at 44% in 2025, while Asia-Pacific is anticipated to register the fastest growth through 2034.

Pharmacovigilance and drug safety software is the set of applications used to collect, process, assess, report, and monitor adverse events and safety data across the lifecycle of a medicinal product, from clinical development through post-marketing surveillance. The software supports the intake and processing of individual case safety reports, the electronic submission of reports to regulators in the ICH E2B format, medical coding with the Medical Dictionary for Regulatory Activities and the World Health Organization Drug Dictionary, the detection and management of safety signals, the preparation of aggregate reports such as periodic safety update reports and development safety update reports, and the management of risk management plans. Leading platforms combine these capabilities into unified suites, including Oracle Argus and Empirica within Safety One, ArisGlobal LifeSphere MultiVigilance, Veeva Vault Safety with Vault Signal and SafetyDocs, the IQVIA Vigilance Platform, and the SafetyEasy suite powered by AB Cube. The workflow proceeds from case intake and triage through processing, coding, and medical review to regulatory submission, signal detection, and risk management, and the contemporary market is defined by the shift from on-premise systems to cloud deployment and by the integration of natural language processing and generative artificial intelligence to automate intake, coding, and narrative generation.

Pharmacovigilance and Drug Safety Software Market Key Growth Drivers

• Rising volume of adverse event reports, with the European Medicines Agency reporting that EudraVigilance contained 29.3 million individual case safety reports, representing 16.9 million unique cases, by early 2024.
• Mandatory electronic reporting standards, with the European Medicines Agency requiring the ICH E2B (R3) format for electronic individual case safety report submission to EudraVigilance and the U.S. Food and Drug Administration structuring its FAERS database to the ICH E2B guidance.
• Tightening global pharmacovigilance regulation, including the European Union Good Pharmacovigilance Practices modules, United States requirements under 21 CFR Part 11 and the post-marketing reporting rules, and the harmonized ICH guidelines.
• Rapid adoption of artificial intelligence and automation, with vendors including ArisGlobal, Oracle, Veeva Systems, and IQVIA embedding natural language processing and generative artificial intelligence to automate case intake, medical coding, and narrative generation.
• A pronounced shift toward cloud and software-as-a-service deployment that lowers infrastructure cost and accelerates implementation across pharmaceutical companies of every size.
• Growth of the biopharmaceutical pipeline and expanding product launches that increase the number of products under active safety surveillance.
• Expansion of multivigilance and real-world data sources, including medical device vigilance, cosmetovigilance, literature, and digital channels, that widen the scope and volume of safety data.

Key Companies in Pharmacovigilance and Drug Safety Software Market

The competitive field is led by large platform vendors that offer end-to-end safety suites, challenged by specialist multivigilance and modernization vendors and by regional providers. The leading participants in the pharmacovigilance and drug safety software market include the following:

• Oracle Corporation
• Veeva Systems Inc.
• ArisGlobal LLC
• IQVIA Holdings Inc.
• EXTEDO GmbH
• AB Cube SAS
• Ennov SAS
• Sarjen Systems Pvt. Ltd.
• Max Application SAS
• United BioSource LLC

Factors Contributing to the Growth of the Pharmacovigilance and Drug Safety Software Market

Market Drivers

Rising Volume of Adverse Event Reports and Individual Case Safety Reports

The foundational driver of the pharmacovigilance and drug safety software market is the sustained growth in the volume of adverse event reports and individual case safety reports that safety teams must process, code, and submit within regulatory timelines. The European Medicines Agency has reported that EudraVigilance, its central database for adverse event reports across the European Union and European Economic Area, contained 29.3 million individual case safety reports, representing 16.9 million unique cases, by early 2024, a dataset comparable in scale to the FAERS database maintained by the U.S. Food and Drug Administration. The volume continues to rise as patient reporting expands, as digital and social channels generate new sources of safety data, and as the biopharmaceutical pipeline widens the number of products under surveillance. Manual processing cannot scale to this volume within the timelines that regulators require, which compels pharmaceutical companies, contract research organizations, and outsourcing providers to adopt software that automates intake, triage, coding, and submission. The recurring and mandatory nature of case processing makes adverse event reporting and case management the core of every safety deployment and the largest driver of software demand. As report volumes grow with product launches, patient engagement, and the broadening of vigilance to devices and other product types, the requirement for scalable, compliant, and increasingly automated case management sustains steady expansion of the market.

Tightening Global Pharmacovigilance Regulations and Standards

A tightening and harmonization of global pharmacovigilance regulation has raised the compliance bar and expanded demand for validated safety software. The European Medicines Agency requires the ICH E2B(R3) format for the electronic submission of individual case safety reports to EudraVigilance, and it enforces the Good Pharmacovigilance Practices modules that govern signal management, risk management, and periodic reporting across the European Union. The U.S. Food and Drug Administration structures its adverse event database to the ICH E2B guidance, codes events with the Medical Dictionary for Regulatory Activities, and requires expedited and periodic reporting under its post-marketing rules, while 21 CFR Part 11 governs electronic records and signatures. The International Council for Harmonisation guidelines standardize the format and content of safety reporting across regions, and national authorities including the Pharmaceuticals and Medical Devices Agency in Japan and the National Medical Products Administration in China maintain their own electronic reporting requirements. These obligations compel companies to operate validated systems that produce compliant electronic submissions, maintain audit trails, and support signal and risk management workflows aligned to the Good Pharmacovigilance Practices. Because the requirements are mandatory, evolving, and multi-regional, they favor software that is continuously updated for regulatory change and that supports submission to multiple authorities from a single platform, sustaining durable demand for compliant pharmacovigilance and drug safety software.

Market Restraints

The pharmacovigilance and drug safety software market faces several interrelated restraints that temper its growth. The foremost is the high cost and complexity of implementation and validation, since safety systems must be configured to each organization's processes, integrated with clinical, regulatory, and quality systems, and validated to demonstrate compliance with 21 CFR Part 11, the Good Pharmacovigilance Practices, and the ICH guidelines, which requires time, specialized expertise, and capital that can be prohibitive for smaller organizations. Migration from entrenched legacy on-premise databases to modern cloud platforms is disruptive and carries risk to data integrity and business continuity, and the effort of transferring large historical case volumes and revalidating workflows slows replacement decisions. Data privacy and security obligations, including the General Data Protection Regulation in Europe and the handling of sensitive personal and health data across borders, add compliance burden and constrain the movement of data to cloud environments, requiring anonymization and localization that increase complexity. The shortage of experienced pharmacovigilance and safety informatics professionals limits the capacity of organizations to implement and operate advanced systems and to validate artificial intelligence tools. The adoption of artificial intelligence, while a powerful driver, raises questions of regulatory acceptance, explainability, and data quality, since automated coding and narrative generation must be validated and auditable to satisfy regulators, and the evolving regulatory posture toward artificial intelligence in safety introduces uncertainty. Integration with the wider ecosystem of clinical trial, regulatory information management, and quality systems is technically demanding, and the multiplicity of regional reporting requirements adds ongoing maintenance cost. Reliance on outsourcing and the concentration of the installed base among a few large platform vendors can raise switching costs and constrain the flexibility of smaller providers. Together these factors moderate the pace of adoption and modernization and require vendors to demonstrate clear compliance, efficiency, and cost advantages to sustain growth.

Pharmacovigilance and Drug Safety Software Market Segment Analysis

The global spinal stenosis devices market is segmented by software type (adverse event reporting and case management, signal detection and management, risk management, regulatory and aggregate reporting, medical coding and dictionary management, and fully integrated safety suites), by delivery mode (on-premise, cloud-based), by end-user (pharmaceutical and biotechnology companies, contract research organizations, business process outsourcing firms, regulatory authorities and government agencies, and others), and by geography (North America, Europe, Asia-Pacific, and the Rest of the World).

By Software Type

Dominant Subsegment: Adverse Event Reporting and Case Management.

The adverse event reporting and case management category is expected to dominate the market. The adverse event reporting and case management segment accounted for a 38% share of the pharmacovigilance and drug safety software market in 2025. Case management is the core of every safety deployment, encompassing the intake, triage, processing, medical review, and electronic submission of individual case safety reports, and it is required continuously and at scale for every product under surveillance. Its dominance reflects the mandatory and recurring nature of case processing and the volume of reports that safety teams must handle within regulatory timelines. Every leading platform is built upon this capability, including Oracle Argus, ArisGlobal LifeSphere MultiVigilance, Veeva Vault Safety, the IQVIA Vigilance Platform, and the SafetyEasy suite powered by AB Cube, and the segment benefits directly from the automation wave, as vendors embed natural language processing and generative artificial intelligence to accelerate intake, coding, and narrative generation. The requirement to produce compliant electronic submissions in the ICH E2B (R3) format, to code events with the Medical Dictionary for Regulatory Activities, and to maintain audit trails concentrates value in validated case management systems. As report volumes rise with product launches, patient reporting, and the broadening of vigilance to additional product types, and as organizations modernize legacy systems to gain automation, case management remains the largest and most defensible segment. Its centrality to compliance and its exposure to the artificial intelligence modernization cycle sustain its leadership across the forecast period and anchor demand for the safety platforms supplied by the leading vendors.

By Delivery Mode

Dominant Subsegment: Cloud-Based.

The cloud-based category is expected to dominate the market. The cloud-based segment accounted for a 58% share of the pharmacovigilance and drug safety software market in 2025. Cloud and software-as-a-service delivery has become the default for modern safety platforms because it lowers infrastructure and maintenance cost, accelerates implementation and validation, scales capacity with case volume, and enables continuous regulatory updates and unified global access. Its dominance reflects the industry-wide migration from legacy on-premise databases toward cloud platforms and the preference of new adopters for rapid, low-capital deployment. Veeva Vault Safety is delivered as a cloud application on a single platform, the IQVIA Vigilance Platform is a secure software-as-a-service environment, the SafetyEasy suite powered by AB Cube is a cloud service that can be configured and validated within a short period, and Oracle has moved its safety solutions onto Oracle Cloud Infrastructure. Cloud delivery is especially important for emerging biotechnology companies and for contract research and outsourcing providers that require rapid deployment without large capital investment, and it enables the integration of artificial intelligence services and external data sources that on-premise systems cannot easily accommodate. As organizations migrate to reduce cost, improve scalability, and access automation, the cloud-based segment leads the market and drives replacement demand. The alignment of cloud delivery with the artificial intelligence modernization cycle and with the needs of organizations of every size sustains its leadership across the forecast period.

Pharmacovigilance and Drug Safety Software Market Region Analysis

Dominant Region: North America

North America accounted for a 44% share of the global pharmacovigilance and drug safety software market in 2025, representing the highest regional market share globally. The leadership of the region reflects the concentration of the global pharmaceutical and biotechnology industry, the presence of the leading safety software vendors, a stringent and well-defined regulatory framework, and the early adoption of cloud and artificial intelligence in pharmacovigilance. The United States is the largest national market, supported by the size of its biopharmaceutical sector, the volume of adverse event reports processed, and the rigor of the U.S. Food and Drug Administration post-marketing safety surveillance program. The agency maintains the FAERS database within its adverse event monitoring system, structures reporting to the ICH E2B guidance, codes events with the Medical Dictionary for Regulatory Activities, and enforces electronic records requirements under 21 CFR Part 11, and it operates the Sentinel initiative for active surveillance using real-world data. The leading vendors, including Oracle, Veeva Systems, ArisGlobal, and IQVIA, are headquartered or heavily operate in the region, which accelerates the adoption of new platforms and artificial intelligence capabilities. The concentration of large pharmaceutical organizations with global safety obligations, the availability of capital for modernization, and the maturity of cloud adoption reinforce the leadership of the region. The combination of industry concentration, regulatory rigor, vendor presence, and early adoption of automation sustains the position of North America as the largest regional market across the forecast period.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is projected to register the fastest compound annual growth rate through 2034. The region is expanding its biopharmaceutical industry, clinical trial activity, and regulatory infrastructure, and it is building the pharmacovigilance capacity required to support that growth, which drives demand for safety software. China, Japan, and India are the principal national markets, supported by growing domestic pharmaceutical sectors, rising clinical trial volumes, and the strengthening of pharmacovigilance requirements by the National Medical Products Administration in China, the Pharmaceuticals and Medical Devices Agency in Japan, and the regulatory authorities in India. India is also a major global center for pharmacovigilance outsourcing, hosting the safety operations of many contract research and business process outsourcing providers that adopt safety software at scale. As national authorities strengthen electronic reporting and signal management requirements, and as domestic companies expand their portfolios and international presence, organizations adopt compliant, cloud-based, and increasingly automated safety platforms. The combination of industry expansion, regulatory strengthening, outsourcing concentration, and rising adoption of cloud and artificial intelligence positions Asia-Pacific as the fastest-growing regional market, and it attracts investment and commercial focus from the leading global vendors seeking presence in high-growth national markets.

Regional Commentary

North America

North America leads the market, supported by the concentration of the global pharmaceutical and biotechnology industry, the presence of the leading safety software vendors, and a stringent regulatory framework. The United States dominates the region through the size of its biopharmaceutical sector, the rigor of the U.S. Food and Drug Administration post-marketing surveillance program, and the early adoption of cloud and artificial intelligence. The concentration of large safety organizations with multi-regional obligations and the availability of capital for modernization sustain demand for comprehensive, validated safety platforms.

Europe

Europe is a mature and substantial market, shaped by the European Medicines Agency and its EudraVigilance system, the Good Pharmacovigilance Practices modules, and the requirement for the ICH E2B (R3) format for electronic reporting. Germany, France, Italy, Spain, and the United Kingdom are the principal national markets, supported by strong regulatory rigor, the presence of European specialists including EXTEDO, AB Cube, and Ennov, and the activity of the Pharmacovigilance Risk Assessment Committee. Demand is sustained by multi-regional compliance obligations and by the strengthening of signal and risk management requirements.

Asia-Pacific

Asia-Pacific is the fastest-growing region, driven by the expansion of the biopharmaceutical industry, rising clinical trial activity, and the strengthening of pharmacovigilance requirements across China, Japan, and India. India is a major global center for pharmacovigilance outsourcing, and the adoption of cloud-based and automated safety platforms is rising as regulatory requirements and portfolios grow. The region attracts commercial focus from the leading global vendors seeking presence in high-growth national markets.

Rest of World

The Rest of World, spanning Latin America, the Middle East, and Africa, represents an emerging opportunity as regulatory authorities strengthen pharmacovigilance requirements and as domestic pharmaceutical industries expand. Growth is supported by the adoption of electronic reporting, the participation of national authorities in the World Health Organization program for international drug monitoring, and rising awareness of safety obligations, though the adoption of advanced and cloud-based software varies by market. Vendors pursue these markets through cloud delivery and partnerships suited to developing regulatory infrastructure.

Pharmacovigilance and Drug Safety Software Market Competitive Landscape

The global pharmacovigilance and drug safety software market is classified as Moderately Consolidated. A small group of large platform vendors dominates the market through comprehensive, end-to-end safety suites, strong installed bases among large pharmaceutical organizations, global delivery, and continuous investment in artificial intelligence, while specialist multivigilance and modernization vendors and regional providers compete on differentiated technology, cost, and rapid deployment. Competition centers on automation, cloud delivery, signal detection, regulatory conformity, and the breadth of the safety suite, and product launches, artificial intelligence introductions, and platform migrations intensify the contest. The competitive landscape is evaluated across the following dimensions:

• Market concentration: Moderately consolidated, with a small group of large platform vendors holding the majority of global revenue through comprehensive safety suites, alongside a tier of specialist multivigilance and modernization vendors and regional providers.
• Leading players: Oracle, with Argus and Empirica within Safety One, and Veeva Systems, with Vault Safety, Vault Signal, and SafetyDocs, lead alongside ArisGlobal, with LifeSphere MultiVigilance and NavaX, and IQVIA, with its Vigilance Platform, while EXTEDO, AB Cube, and Ennov contest defined segments with the SafetyEasy suite and specialist multivigilance offerings.
• Geographic reach: The leading vendors maintain global delivery and support organizations, while European specialists and regional providers leverage local relationships and rapid, cost-effective deployment to serve their domestic and neighboring markets.
• Product portfolio strength: Competitive advantage rests on breadth across case intake and processing, signal detection and management, risk management, aggregate reporting, and medical coding within a unified platform, since organizations increasingly consolidate safety operations onto a single suite rather than assembling point solutions.
• Pipeline strength: Development is concentrated in generative artificial intelligence and natural language processing for intake, coding, and narrative generation, in cloud and software-as-a-service delivery, in signal detection using real-world and external data, and in multivigilance across drugs, devices, and other product types.
• Strategic partnerships: Collaboration spans implementation and validation partners, integration with clinical, regulatory, and quality systems, and alliances that extend delivery and support reach across regions.
• M&A activity: Consolidation has shaped the field as large platform vendors and private capital have acquired and integrated safety and regulatory technology, and as vendors extend their suites across the safety and regulatory lifecycle.
• Innovation focus: Innovation is shifting toward generative artificial intelligence and automation across the safety workflow, cloud-native delivery, unified multivigilance, and signal detection that incorporates real-world data and digital sources.
• Regulatory standing: Conformity with the ICH E2B(R3) format, the Good Pharmacovigilance Practices, 21 CFR Part 11, and the multi-regional electronic reporting requirements is a decisive competitive credential, and the ability to update continuously for regulatory change has become a principal axis of competition among the leaders.

Pharmacovigilance and Drug Safety Software Market Recent Developmental Activities

In June 2025, ArisGlobal LLC announced that a sixth global pharmaceutical company selected LifeSphere NavaX, its generative artificial intelligence cognitive computing engine, to enhance case processing, with the organization processing 150,000 adverse event cases each year on the LifeSphere MultiVigilance platform and targeting efficiency gains of 65% and intake accuracy of 90%. Strategic significance: the adoption confirmed the industry shift from piloting artificial intelligence to scaling it across global case processing operations in the dominant case management segment.

In March 2025, ArisGlobal LLC announced that a fifth global biopharmaceutical company, processing 400,000 adverse event cases each year on the LifeSphere MultiVigilance platform, selected LifeSphere NavaX to enhance case processing with generative artificial intelligence. Strategic significance: the win reinforced the momentum of artificial intelligence adoption among the largest safety organizations and the modernization of legacy case processing.

Pharmacovigilance and Drug Safety Software Market Segmentation

Pharmacovigilance and Drug Safety Software Market Assessment by Software Type

• Adverse Event Reporting and Case Management
• Signal Detection and Management
• Risk Management
• Regulatory and Aggregate Reporting
• Medical Coding and Dictionary Management
• Fully Integrated Safety Suites

Pharmacovigilance and Drug Safety Software Market Assessment by Delivery Mode

• On-Premise
• Cloud-Based

Pharmacovigilance and Drug Safety Software Market Assessment by End-User

• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations
• Business Process Outsourcing Firms
• Regulatory Authorities and Government Agencies
• Others

Pharmacovigilance and Drug Safety Software Market Assessment by Geography

• North America
• United States Pharmacovigilance and Drug Safety Software Market Size in USD million (2023-2034)
• Canada Pharmacovigilance and Drug Safety Software Market Size in USD million (2023-2034)
• Mexico Pharmacovigilance and Drug Safety Software Market Size in USD million (2023-2034)
• Europe
• France Pharmacovigilance and Drug Safety Software Market Size in USD million (2023-2034)
• Germany Pharmacovigilance and Drug Safety Software Market Size in USD million (2023-2034)
• United Kingdom Pharmacovigilance and Drug Safety Software Market Size in USD million (2023-2034)
• Italy Pharmacovigilance and Drug Safety Software Market Size in USD million (2023-2034)
• Spain Pharmacovigilance and Drug Safety Software Market Size in USD million (2023-2034)
• Rest of Europe Pharmacovigilance and Drug Safety Software Market Size in USD million (2023-2034)
• Asia-Pacific
• China Pharmacovigilance and Drug Safety Software Market Size in USD million (2023-2034)
• Japan Pharmacovigilance and Drug Safety Software Market Size in USD million (2023-2034)
• India Pharmacovigilance and Drug Safety Software Market Size in USD million (2023-2034)
• Australia Pharmacovigilance and Drug Safety Software Market Size in USD million (2023-2034)
• South Korea Pharmacovigilance and Drug Safety Software Market Size in USD million (2023-2034)
• Rest of Asia-Pacific Pharmacovigilance and Drug Safety Software Market Size in USD million (2023-2034)
• Rest of the World
• Middle East Pharmacovigilance and Drug Safety Software Market Size in USD million (2023-2034)
• Africa Pharmacovigilance and Drug Safety Software Market Size in USD million (2023-2034)
• South America Pharmacovigilance and Drug Safety Software Market Size in USD million (2023-2034)

Key Takeaways from the Pharmacovigilance and Drug Safety Software Market Report Study

• Market size analysis for the current pharmacovigilance and drug safety software market size (2025), and market forecast for 9 years (2026 to 2034).
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
• Key companies dominating the global pharmacovigilance and drug safety software market.
• Various opportunities available for competitors in the pharmacovigilance and drug safety software market space.
• What are the top-performing segments in 2025? How will these segments perform in 2034?
• Which are the top-performing regions and countries in the current pharmacovigilance and drug safety software market scenario?
• Which are the regions and countries where companies should concentrate their opportunities for pharmacovigilance and drug safety software market growth in the future?

Target audience who can benefit from this pharmacovigilance and drug safety software market report study

• Pharmacovigilance and drug safety software product providers
• Research organizations and consulting companies
• Pharmacovigilance and drug safety software-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in pharmacovigilance and drug safety software
• Various end-users who want to know more about the pharmacovigilance and drug safety software market and the latest technological developments in the pharmacovigilance and drug safety software market.

Frequently Asked Questions:

Q1. At what rate is the pharmacovigilance and drug safety software market expected to grow?

The global pharmacovigilance and drug safety software market is projected to grow at a compound annual growth rate of 10.4% during the forecast period from 2026 to 2034.

Q2. What is the current and projected size of the pharmacovigilance and drug safety software market?

The global pharmacovigilance and drug safety software market was valued at USD 1.62 billion in 2025 and is projected to reach USD 3.94 billion by 2034.

Q3. Which region dominates the pharmacovigilance and drug safety software market?

North America dominated the pharmacovigilance and drug safety software market with a 44% share in 2025, driven by the concentration of the global pharmaceutical and biotechnology industry, the presence of the leading vendors, a stringent regulatory framework from the U.S. Food and Drug Administration, and early adoption of cloud and artificial intelligence, with the agency maintaining the FAERS database structured to the ICH E2B guidance. Asia-Pacific is projected to record the fastest compound annual growth rate through 2034, driven by the expansion of the biopharmaceutical industry, rising clinical trial activity, and the concentration of pharmacovigilance outsourcing across China, Japan, and India.

Q4. What are the key factors driving growth in the pharmacovigilance and drug safety software market?

The principal drivers are the rising volume of adverse event reports, with the European Medicines Agency reporting that EudraVigilance contained 29.3 million individual case safety reports by early 2024; tightening global regulation, including the ICH E2B(R3) reporting format, the European Union Good Pharmacovigilance Practices, and 21 CFR Part 11; the adoption of artificial intelligence and automation across case intake, coding, and signal detection; the shift toward cloud and software-as-a-service deployment; and the expansion of the biopharmaceutical pipeline and of multivigilance across product types.

Q5. Who are the major players in the pharmacovigilance and drug safety software market?

The market is moderately consolidated and led by Oracle Corporation, Veeva Systems Inc., ArisGlobal LLC, and IQVIA Holdings Inc., alongside EXTEDO GmbH, AB Cube SAS, Ennov SAS, Sarjen Systems Pvt. Ltd., Max Application SAS, and United BioSource LLC. Additional participants including Clinevo Technologies, Sparta Systems, PharmaLex, and Anju Software compete across case management, signal detection, regulatory reporting, and multivigilance.